Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
GLP-1 Drugs Reshaping Spending on Food and Beauty - Featured image
GLP-1 Medications

GLP-1 Drugs Reshaping Spending on Food and Beauty

Dr. Adrian Vale, MD
Reviewed by Dr. Adrian Vale, MDInternal Medicine · Board-Certified Obesity Medicine
·January 15, 2026·2 min read

On this page

  • Circana Tracks GLP-1 User Spending Habits
  • Increased Spending on Beauty and Self-Care
  • Protein Product Boom Driven by GLP-1 Use
  • Opportunities for Functional Foods
  • Pre-Existing Trends Among Weight-Conscious Shoppers

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

Weight loss drugs like GLP-1 medications are transforming consumer spending patterns. New Circana research reveals users cut grocery costs by 2% but increase outlays on beauty and self-care items. Protein-focused products surge 40% as users combat muscle loss side effects.

Share

On this page

  • Circana Tracks GLP-1 User Spending Habits
  • Increased Spending on Beauty and Self-Care
  • Protein Product Boom Driven by GLP-1 Use
  • Opportunities for Functional Foods
  • Pre-Existing Trends Among Weight-Conscious Shoppers

GLP-1 medications, such as Ozempic, Wegovy, and Mounjaro, are revolutionizing how people allocate their budgets during weight loss journeys.

Over 400,000 Australians currently use these GLP-1 weight loss drugs, which can cost up to $5,000 annually depending on dosage strength and eligibility for subsidies like the Pharmaceutical Benefit Scheme.

Circana Tracks GLP-1 User Spending Habits

Market research firm Circana monitors household spending for GLP-1 users in Australia and conducts detailed analysis in the US.

US data shows a 2% decline in food and beverage spending during 6-12 months of GLP-1 use, with spending rebounding after discontinuation.

Pre-Existing Trends Among Weight-Conscious Shoppers

Circana Insights Director Daniel Bone notes that GLP-1 users often already spend more on food and beverages.

  • 46% of Australians buy weight management products for themselves or household members.
  • These shoppers spend 10% more in pharmacies on average.
  • Grocery spending matches the general population, but shifts across categories.
"Just because you are focused on weight management doesn't necessarily mean that you are inherently spending less, it just influences how you are distributing your spend across product categories," said Bone.

Increased Spending on Beauty and Self-Care

GLP-1 users boost spending in self-care and beauty products, partly to address medication side effects.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play

"That results in high levels of spending on health and beauty products... there is a discernible uplift in spending," Bone explained.

Protein Product Boom Driven by GLP-1 Use

Australian supermarkets see protein-led products grow 40% year-on-year—six times the overall grocery rate.

GLP-1 medications cause weight loss including muscle mass, prompting users to seek protein-forward foods.

"There is that growing understanding that one of the side effects of using GLP-1 is that you're losing weight, but you're losing muscle mass as well," Bone stated.

This trend accelerates launches of protein-rich items across categories, marketed to appeal to weight loss drug users without direct GLP-1 branding.

Opportunities for Functional Foods

GLP-1 users prioritize products high in protein, fiber, nutrients, or smaller portions to optimize medication outcomes.

  • Creates premiumization chances for higher-priced functional health items.
  • Demand spikes during use, normalizing post-discontinuation.

Bone predicts oral GLP-1 pills in Australia will expand adoption, intensifying trends in beauty, pharmacy, groceries, and functional foods.

Source Information

Originally published by Perth Now.Read the original article →

Read next

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Beyond the Scale: GLP-1 Users & the Exercise Paradox
Health & Wellness

Beyond the Scale: GLP-1 Users & the Exercise Paradox

While GLP-1 medications have revolutionized weight loss, a recent study indicates a concerning trend: users may be reducing their physical activity. This article explores the findings and emphasizes the continued importance of exercise.

7 min read
Ozempic, Wegovy & Mounjaro: Navigating Dizziness and Fainting Risks
Health & Wellness

Ozempic, Wegovy & Mounjaro: Navigating Dizziness and Fainting Risks

Recent research highlights a potential safety concern with GLP-1 medications, linking them to an increased risk of dizziness and fainting, particularly in certain patient groups. Discover what this means for your health.

6 min read
GLP-1 Revolution in India: Affordability Meets Accessibility in Obesity Fight
Health Technology & Access

GLP-1 Revolution in India: Affordability Meets Accessibility in Obesity Fight

The advent of affordable, locally produced GLP-1 agonists in India marks a significant shift in managing the nation's escalating obesity crisis. For millions like Manoj, these once exclusive medications are now within reach, provided they adhere to strict medical guidance and lifestyle adjustments.

6 min read

Same topic: GLP-1

All GLP-1 articles →
New Obesity Pills in the UAE: Navigating Insurance Coverage for Wegovy and Foundayo
Metabolic Health

New Obesity Pills in the UAE: Navigating Insurance Coverage for Wegovy and Foundayo

As new weight-loss medications enter the UAE market, patients are questioning insurance coverage. We break down the realities of policy, medical necessity, and the future of metabolic health.

2 min read
Medicare Expands GLP-1 Coverage: What the 2027 Policy Shift Means for Seniors
Healthcare Policy

Medicare Expands GLP-1 Coverage: What the 2027 Policy Shift Means for Seniors

The federal government has extended its commitment to fund GLP-1 obesity medications through 2027, shifting away from private insurer mandates to protect seniors from premium hikes.

2 min read
Tirzepatide vs. Semaglutide: A Comprehensive Guide to Cost and Health Outcomes
Medical Research

Tirzepatide vs. Semaglutide: A Comprehensive Guide to Cost and Health Outcomes

A new lifetime economic analysis suggests tirzepatide may offer superior long-term value and clinical outcomes compared to semaglutide for obesity management.

2 min read

More in GLP-1 Medications

Ozempic, Wegovy & Beyond: How GLP-1 Drugs Are Changing What We Eat
Health & Wellness

Ozempic, Wegovy & Beyond: How GLP-1 Drugs Are Changing What We Eat

The rise of GLP-1 medications is profoundly altering consumer spending habits and food preferences, forcing the grocery industry to adapt. Discover the science behind these changes and how businesses are responding.

7 min read
Wegovy, Zepbound & More: Hers Makes GLP-1s Accessible from $39
Health & Wellness

Wegovy, Zepbound & More: Hers Makes GLP-1s Accessible from $39

The journey to weight loss can be challenging, and for many, advanced medications like GLP-1 injectables offer a crucial pathway. However, their high cost often presents a significant barrier. Hers is changing this landscape by making popular GLP-1 and other weight loss treatments more accessible and affordable than ever before.

7 min read
Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise
Medical News

Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise

Eli Lilly has released pivotal Phase 3 trial data for retatrutide, a triple agonist showing up to 28% body weight reduction and significant improvements in diabetes and sleep apnea.

7 min read
Share this article
  1. Home
  2. Blog
  3. GLP-1 Drugs Reshaping Spending on Food and Beauty
Dr. Adrian Vale, MD — Internal Medicine · Board-Certified Obesity Medicine
Medically reviewed

Dr. Adrian Vale, MD

Internal Medicine · Board-Certified Obesity Medicine

Dr. Adrian Vale is a board-certified internal medicine physician with a clinical focus on obesity medicine and metabolic health. He reviews Shotlee guides and articles on GLP-1 medications, peptide therapy, and weight-management protocols for clinical accuracy.

View all articles reviewed by Dr. Adrian Vale, MD
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community